Tuesday, June 11, 2019

Summary Essay Example | Topics and Well Written Essays - 500 words - 59

Summary - Essay Examplein a competitive edge by developing a treatment drug for Alzheimers disease, of which 18 one thousand million people suffer around the world, Pfizer decided in 2008 to give Medivation a large gist of $225 million and $500 million more if it was able to successfully produce Dimebon. The feasibility of the drug as well as the extravagance of the deal were widely criticized, though past evidence from Russia suggested that the development of such a drug was possible.However, when the drug was tested by introducing it to moderate Alzheimers patients in phase 3 trials, it failed to get through the expected goals. Consequently, with the termination of the partnership contract, the dreams of the two companies to gain a substantial edge in the Pharmaceutical industry collapsed too. Since Medivation used to rely heavily on its partnership with Pfizer to generate returns, the extinction of the agreement has resulted in more serious financial losses for Medivation in co ntrast to Pfizer.This is certainly not a levelheaded signal for Medivation as well as Pfizer. The stoppage of the development of Dimebon has caused financial setbacks to both the companies. During the first three quarters of 2011, Medivations shargons remove dropped drastically by 3.3%. At the same time, Pfizers stock rose only slightly by 0.4%. The plans of the two companies to become future leaders in the market have crashed along with their product. Consequently, the financial outcomes are bound to remain low for at least sometime in the future.As far as the competitors of the two companies are concerned, they have been presented with a very good opportunity to gain an edge in the market. The competitors are already aware of the significance which Alzheimers drug holds and the amount of sales it could trigger. Moreover, information about the failure of Medivation and Pfizer in phase 3 trial will result in competitors being further careful in developing the product and avoiding the mistakes which were committed by

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.